PF 06823859

Drug Profile

PF 06823859

Alternative Names: PF06823859

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Biological factors
  • Mechanism of Action Interferon beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lupus vulgaris

Most Recent Events

  • 12 Jun 2017 Pfizer plans a phase II trial for Dermatomyositis in USA (NCT03181893)
  • 16 May 2016 Preclinical trials in Lupus in USA (IV) before May 2016 (NCT02766621)
  • 16 May 2016 Preclinical trials in Lupus in USA (SC) before May 2016 (NCT02766621)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top